Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 14/20 | 0.50 |
| ▸ | GAA | P10253 | 14/20 | 0.50 |
| ▸ | SI | P14410 | 14/20 | 0.50 |
| ▸ | MGAM2 | Q2M2H8 | 14/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | CBFB | Q13951 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6756257 | 0.83 | PARP1 (0.46) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL24995382 | 0.81 | HSD17B10 (0.49) | HSD17B10ALDH1A1HPGDKDM4ELMNA | |
| SCHEMBL6489669 | 0.80 | HSD17B10 (0.47) | HSD17B10ALDH1A1HPGDKDM4ELMNA | |
| SCHEMBL7966359 | 0.80 | MEN1 (0.50) | GAAHSD17B10ALDH1A1HPGDKDM4E | |
| SCHEMBL28871223 | 0.80 | HSD17B10 (0.47) | HSD17B10ALDH1A1HPGDKDM4ELMNA | |
| SCHEMBL1272228 | 0.80 | PSMB8 (0.51) | MGAMGAASIMGAM2HSD17B10 | |
| SCHEMBL29967781 | 0.80 | HSD17B10 (0.47) | HSD17B10ALDH1A1HPGDKDM4ELMNA | |
| SCHEMBL4118985 | 0.80 | HSD17B10 (0.47) | MGAMGAASIMGAM2HSD17B10 | |
| SCHEMBL6757190 | 0.78 | CBFB (0.46) | HSD17B10ALDH1A1HPGDCBFBKDM4E | |
| SCHEMBL19170937 | 0.77 | HSD17B10 (0.51) | HSD17B10ALDH1A1HPGDCBFBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0428260-B1 | Metal surface treatment agents | SANWA LAB LTD (JP) | 2000-01-05 | — | — | EP | claimed |
| EP-0562187-B1 | Process for production of copper through-hole printed wiring boards | SANWA LAB LTD (JP) | 1996-01-10 | — | — | EP | claimed |
| US-5275694-A | Printed circuits with copper through holes, negative patterns, photoresists, lamination, dipping and etching | SANWA LABORATORY LTD. (JP) | 1994-01-04 | — | — | US | claimed |
| EP-0562187-A1 | Process for production of copper through-hole printed wiring boards | SANWA LABORATORY LTD. (JP) | 1993-09-29 | — | — | EP | claimed |
| EP-0428260-A2 | Metal surface treatment agents | SANWA LABORATORY LTD. (JP) | 1991-05-22 | — | — | EP | claimed |
| WO-2023191379-A1 | 3,4-DIHYDROQUINOXALINE-2-CARBOXIMIDE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME FOR PREVENTING OR TREATING CANCER DISEASE | 재단법인 대구경북첨단의료산업진흥재단 | 2023-10-05 | — | — | WO | disclosed |
| WO-2022135365-A1 | DISUBSTITUTED CYCLOPENTANE KINASE INHIBITORS | ANRUI BIOMEDICAL TECHNOLOGY (GUANGZHOU) CO., LTD. (CN) | 2022-06-30 | — | — | WO | disclosed |
| US-20210047287-A1 | NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2021-02-18 | — | — | US | disclosed |
| US-10738030-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-08-11 | — | — | US | disclosed |
| US-20200231547-A1 | 2-(1,1'-BIPHENYL)-1H-BENZODIMIDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS APELIN AND APJ AGONISTS FOR TREATING CARDIOVASCULAR DISEASES | BRISTOL MYERS SQUIBB CO (US) | 2020-07-23 | — | — | US | disclosed |
| US-20190055220-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED | 2019-02-21 | — | — | US | disclosed |
| US-9187496-B2 | 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors | IDENIX PHARMACEUTICALS LLC (US) | 2015-11-17 | — | — | US | disclosed |
| EP-0562187-B1 | Process for production of copper through-hole printed wiring boards | SANWA LAB LTD (JP) | 1996-01-10 | — | — | EP | disclosed |
| US-5275694-A | Printed circuits with copper through holes, negative patterns, photoresists, lamination, dipping and etching | SANWA LABORATORY LTD. (JP) | 1994-01-04 | — | — | US | disclosed |
| EP-0562187-A1 | Process for production of copper through-hole printed wiring boards | SANWA LABORATORY LTD. (JP) | 1993-09-29 | — | — | EP | disclosed |
| EP-0186190-B1 | BENZIMIDAZOLE DERIVATIVES, AND THEIR PRODUCTION AND USE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1993-05-26 | — | — | EP | disclosed |
| EP-0428260-A2 | Metal surface treatment agents | SANWA LABORATORY LTD. (JP) | 1991-05-22 | — | — | EP | disclosed |
| EP-0400835-A1 | Substituted benzimidazoles as angiotensin II antagonists | MERCK & CO. INC. (US) | 1990-12-05 | — | — | EP | disclosed |
| US-4663339-A | Acaricidal and insecticidal substituted 1-phenylalkylbenzimidazoles | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1987-05-05 | — | — | US | disclosed |
| EP-0186190-A2 | Benzimidazole derivatives, and their production and use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1986-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10738030-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1B, SCNN1G | MGAM 3395/4885GAA 1225/4885SI 3456/4885 |
| US-20190055220-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SCNN1G | MGAM 3395/4885GAA 1225/4885SI 3456/4885 |
| US-20200231547-A1 | 2-(1,1'-BIPHENYL)-1H-BENZODIMIDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS APELIN AND APJ AGONISTS FOR TREATING CARDIOVASCULAR DISEASES | APLNR, AP3B1, AP2B1 | MGAM 4150/4885GAA 4290/4885SI 3401/4885 |
| US-20210047287-A1 | NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF | SSTR5, SSTR4, SSTR3 | MGAM 1956/4885GAA 402/4885SI 284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.